Emory is a private institution with a public mission. The University’s vision calls for the Laney Graduate School to be passionate about answering the world’s most pressing questions and driven to improve the lives of others. Investors seeking to make a difference in the world have unlimited opportunities to support life-changing work at the graduate school.
Dennis Liotta has always been good at chemistry. Introduced to atoms and ions by his big brother, Charles, who was a graduate student when Dennis was just 9, the younger Liotta eased into the subject like it was a favorite pair of sneakers. This intellectual comfort afforded him the luxury of creativity. His career as a chemist has been marked by innovation, excitement, and remarkable success, and he has shared his academic ability with Emory since 1976.
As the Samuel Candler Dobbs Professor of Chemistry, he collaborated with colleagues and a team of the nation’s best graduate students to develop a new drug compound to treat HIV infection. Called Emtriva and approved in 2003, the compound is now used by 94 percent of all Americans with HIV. Its licensing agreement provided millions of dollars to the University’s research enterprise, which is seeking treatments and cures for everything from Alzheimer’s to drug addiction. For Liotta, Emory affords the perfect balance of mind and heart, a challenging place to exercise his expertise and fulfill what he considers its accompanying responsibility: to improve the quality of life through scholarship.
Your investment in the Laney Graduate School will provide extraordinary opportunities to advance inquiry and prepare the next generation of scholars.
